The Conversation (0)
Theravance, Inc. (NASDAQ:THRX) has begun the dose-ranging Phase 2b Study 0117 with TD-4208 as a nebulized aqueous solution in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Theravance, Inc. (NASDAQ:THRX) has begun the dose-ranging Phase 2b Study 0117 with TD-4208 as a nebulized aqueous solution in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
As quoted in the press release:
The Phase 2b study will evaluate the bronchodilator effect, safety and tolerability of four doses of TD-4208 and placebo in patients with moderate to severe COPD. Approximately 350 patients will be randomized to receive one of four doses of TD-4208 inhalation solution (44 mcg, 88 mcg, 175 mcg, 350 mcg) or placebo once daily via a jet nebulizer for 28 days in a double-blind, parallel group study design.
Click here to read the Theravance Inc. (NASDAQ:THRX) press release
